Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial.
Adult
Age Factors
DNA, Viral
/ genetics
Double-Blind Method
Female
Global Health
/ statistics & numerical data
Humans
Incidence
Middle Aged
Molecular Diagnostic Techniques
/ statistics & numerical data
Papillomaviridae
/ classification
Papillomavirus Infections
/ epidemiology
Papillomavirus Vaccines
/ administration & dosage
Prevalence
Risk Factors
Vaccination
Young Adult
Adult women
HPV vaccine
Human papillomavirus
Incidence
Persistent infection
Risk factor
Journal
Papillomavirus research (Amsterdam, Netherlands)
ISSN: 2405-8521
Titre abrégé: Papillomavirus Res
Pays: Netherlands
ID NLM: 101662552
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
12
2019
revised:
31
03
2020
accepted:
11
05
2020
pubmed:
29
5
2020
medline:
28
8
2021
entrez:
29
5
2020
Statut:
ppublish
Résumé
The natural history of human papillomavirus (HPV) infection has been studied extensively in young women; this study investigated HPV infection in adult women. Data from 3817 women aged 24-45 years in a global trial of the 4-valent HPV (6/11/16/18) vaccine were used to calculate prevalence of anogenital infections containing 9-valent (9v) HPV vaccine types (6/11/16/18/31/33/45/52/58) and five non-vaccine types (35/39/51/56/59). Incidence of infections and persistent infections was estimated for 989 placebo recipients naive to all 14 HPV types at baseline. Age-adjusted hazard ratios were calculated for various sociodemographic factors. Prevalence of anogenital infection was highest in France at 29.2% (9vHPV types) and 21.7% (non-vaccine types) and lowest in the Philippines at 7.6% (9vHPV types) and 5.1% (non-vaccine types). Overall, HPV incidence (per 100 person-years) was 5.2 (9vHPV types) and 4.7 (non-vaccine types), and incidence of persistent infection was 2.7 (9vHPV types) and 2.1 (non-vaccine types). Factors associated with new HPV infections included younger age, younger age at first intercourse, being single, current use of tobacco, and higher number of past and recent sex partners. Because mid-adult women acquire new HPV infections, administration of the 9vHPV vaccine could reduce HPV-related morbidity and mortality in this population.
Identifiants
pubmed: 32464334
pii: S2405-8521(20)30011-2
doi: 10.1016/j.pvr.2020.100202
pmc: PMC7453107
pii:
doi:
Substances chimiques
DNA, Viral
0
Papillomavirus Vaccines
0
Types de publication
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100202Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Références
J Infect Dis. 2005 Jun 1;191(11):1796-807
pubmed: 15871111
Clin Infect Dis. 2016 Aug 15;63(4):519-27
pubmed: 27230391
Can Commun Dis Rep. 2007 Feb 15;33(ACS-2):1-31
pubmed: 17520773
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1997-2008
pubmed: 25274978
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Int J Cancer. 2001 Feb 1;91(3):412-20
pubmed: 11169968
J Infect Dis. 2009 Mar 15;199(6):805-14
pubmed: 19199546
J Adolesc Health. 2008 Oct;43(4 Suppl):S5-25, S25.e1-41
pubmed: 18809145
Expert Rev Vaccines. 2017 Nov;16(11):1119-1139
pubmed: 28956458
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Lancet Oncol. 2005 May;6(5):271-8
pubmed: 15863374
Vaccine. 2006 Mar 30;24 Suppl 1:S1-15
pubmed: 16406226
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
Eur J Cancer. 2013 Nov;49(16):3450-61
pubmed: 23886586
Prev Med. 2017 Oct;103:60-65
pubmed: 28765084
Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
CMAJ. 2003 Feb 18;168(4):421-5
pubmed: 12591782
Int J Cancer. 2012 Dec 15;131(12):2929-38
pubmed: 22488743
Eur J Cancer. 2015 Sep;51(13):1732-41
pubmed: 26121913
JNCI Cancer Spectr. 2019 Jan 07;2(4):pky045
pubmed: 31360870
Obstet Gynecol. 2006 Jan;107(1):18-27
pubmed: 16394035
Head Neck. 2013 May;35(5):747-55
pubmed: 22267298
Vaccine. 2004 Dec 16;23(5):569-78
pubmed: 15630792
Prev Med. 2017 Jul;100:243-247
pubmed: 28502575
N Engl J Med. 1998 Feb 12;338(7):423-8
pubmed: 9459645
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
MMWR Morb Mortal Wkly Rep. 2019 Apr 19;68(15):337-343
pubmed: 30998672
Clin Microbiol Infect. 2016 Dec 1;22 Suppl 5:S125-S127
pubmed: 28034371
PLoS One. 2013 Nov 19;8(11):e79260
pubmed: 24260180
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702
pubmed: 31415491
J Infect Dis. 2010 Dec 15;202(12):1789-99
pubmed: 21067372
J Infect Dis. 2018 Jan 4;217(2):208-212
pubmed: 29136168
Int J Cancer. 2016 May 15;138(10):2428-38
pubmed: 26685704
J Infect Dis. 1999 Nov;180(5):1415-23
pubmed: 10515798
Lancet. 2009 Jun 6;373(9679):1949-57
pubmed: 19493565